Stockscreener 앱 받기
189.68
0.51%
-0.97
시간 외 거래:
189.68
Repligen Corp 주식(RGEN)의 최신 뉴스
Form 4 Repligen Corporation For: 26 September By Investing.com - Investing.com India
Repligen CEO Loeillot sells $2.46m in shares - Investing.com
Repligen CEO Loeillot sells $2.46m in shares By Investing.com - Investing.com Australia
Repligen Corp (RGEN) CEO Olivier Loeillot Sells 12,946 Shares - GuruFocus
Repligen (RGEN) CEO sells shares at $190 each after exercising options under a trading plan. - Stock Titan
Repligen Corporation (RGEN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Repligen Corporation (RGEN) stock price, news, quote and history - Yahoo Finance UK
Form 144 REPLIGEN CORP For: 24 September By Investing.com - Investing.com Nigeria
Repligen Corporation (RGEN) Stock Forecasts - Yahoo Finance
Is Repligen Corp (RGEN) Overvalued After 3.3% Rally? GF Value Sa - GuruFocus
Shares valued at $2.46 million are listed for sale by a Repligen (NASDAQ: RGEN) officer and director. - Stock Titan
Repligen Corp Stock Baskets - GuruFocus
Repligen Corp (BSP:R2GE34) Stock Price & 30 Year Financial Data - GuruFocus
Repligen Corporation stock hits 52-week high at 188.95 USD - Investing.com
Repligen Corp (RGEN) CEO Olivier Loeillot Sells 5,426 Shares - GuruFocus
Repligen Corp (RGEN) Stock Up 3.3% but GF Value Says Overvalued -- GF Score: 87/100 - GuruFocus
Repligen (RGEN) CEO sells 5,426 shares under plan - Stock Titan
Biolife Solutions stock hits 52-week high at $38.10 By Investing.com - Investing.com Canada
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290 - Zacks Investment Research
Repligen (NASDAQ: RGEN) insider plans new stock sale after two recent trades - Stock Titan
Repligen Stock Price Forecast. Should You Buy RGEN? - StockInvest.us
Repligen (NASDAQ: RGEN) Director Karen Dawes to Step Down on September 30, 2026 - Kalkine Media
Karen A. Dawes to Retire from Repligen Board Effective Sept 30, 2026 - TradingView
Could Pricing Pressure Change the Repligen (NASDAQ:RGEN) Story? - Kalkine Media
BioLife Solutions merger with Repligen advances as antitrust waiting period ends - Investing.com
BioLife Solutions' HSR Antitrust Waiting Period Ends Ahead of Repligen Merger - Kalkine Media
Repligen at Wells Fargo conference: growth broadens beyond headwinds - Investing.com
REPLIGEN CEO Loeillot Olivier Forfeits 2,842 Shares at $169.61 and Sells 3,035 Shares at $165.90 (NASDAQ: RGEN) - Kalkine Media
3 Reasons to Avoid RGEN and 1 Stock to Buy Instead - Yahoo Finance
Repligen to acquire BioLife for $11.25 cash plus 0.1442 shares per BioLife share; HSR waiting period expired - TradingView
[425] REPLIGEN CORP Business Combination Communication | RGEN SEC FilingForm 425 - Stock Titan
Repligen (RGEN) CEO trades stock in preset plan - Stock Titan
Repligen (NASDAQ: RGEN) Schedules October 5 Vote for BioLife Merger Approval - Kalkine Media
REPLIGEN CORP SEC Filing (Sep 8, 2026) - Stock Titan
ZimVie Inc. When-Issued (ZIMVV) Peer Comparison – Compare with Others - Value Research
Repligen Corp (NASDAQ:RGEN) Combines Strong Growth with a Constructive Technical Setup - ChartMill
Repligen Corporation (RGEN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Repligen (RGEN) holder lines up new sale after $976K trade - Stock Titan
Heska Corporation (HSKA) Peer Comparison – Compare with Others - Value Research
What Repligen (NASDAQ: RGEN) plans to pay for each BioLife share - Stock Titan
Repligen (RGEN) Stock Looks Near Fair Value After Recent Rebound - Yahoo Finance
Repligen Offers Differentiated Solutions as a Leading Bioprocessing Supplier - Morningstar
Codex DNA Inc (DNAY) Peer Comparison – Compare with Others - Value Research
Repligen (NASDAQ: RGEN) awards 2,466 stock units to its chief accounting officer - Stock Titan
A Look at Repligen Corp (RGEN) After 6.1% Decline -- GF Value $1 - GuruFocus
Apria Inc. (APR) Peer Comparison – Compare with Others - Value Research
Repligen Shares Slide as Market Weighs BioLife Deal Dilution and Execution Risk - Quiver Quantitative
Acutus Medical Inc (AFIB) Peer Comparison – Compare with Others - Value Research
Repligen Corporation (RGEN) Stock Price, Chart, News & Analysis - securities.io
Repligen Corporation (RGEN) Peer Comparison – Compare with Others - Value Research
Repligen Corp (RGEN) Shares Fall 3.2% -- What GF Score of 87 Tel - GuruFocus
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen - Yahoo Finance
Repligen Corporation to Present at Wells Fargo 21st Annual Healthcare Conference - Yahoo Finance
Repligen (NASDAQ: RGEN) CEO trades shares at $180 under 10b5-1 plan - Stock Titan
LVIP Baron Growth Opportunities Fund's Repligen Corp(RGEN) Holding History - GuruFocus
Repligen rises as investors continue to digest raised 2026 guidance and the BioLife deal - Quiver Quantitative
Repligen (NASDAQ: RGEN) plan covers 5,426-share sale after option exercise - Stock Titan
Repligen (RGEN) Stock Could Be 1% Overvalued Despite Its 45% Run - Yahoo Finance
Repligen Corporation stock hits 52-week high at 176.52 USD By Investing.com - Investing.com South Africa
0.00%
0.47%
자본화:
|
볼륨(24시간):